A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight
← catalyst calendarNCT06151964 · readout in 162 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
166actual
Sites
15
Countries
Austria, Canada, Germany +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-29 | actual | When the study began enrolling |
| Primary completion | 2027-01-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-29 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Overweight and Obesity
Interventions
- Drug: AZD9550
- Drug: placebo
- Drug: AZD9550 and AZD6234
Primary outcomes
what the primary-completion date above is the date OFNumber and percentage of participants with any AE, SAEs, AEs leading to discontinuation of study intervention, AEs with outcome of death, and AEs leading to withdrawal from study.
measured Day - 35 to Day 261
Number and percentage of participants with clinically significant changes from baseline in Vital Sign Parameters.
measured Day - 35 to Day 261
Number and percentage of participants with clinically significant changes in ECG parameters.
measured Day - 35 to Day 261
Number and percentage of participants with clinically significant changes from baseline in Clinical Laboratory Parameters
measured Day - 35 to Day 261
Area Under Concentration-Time Curve of AZD9550 following repeat weekly SC doses
measured Day 1 to Day 65
Maximum observed concentration of AZD9550 following repeat weekly SC doses
measured Day 1 to Day 65
Half life associated with terminal phase elimination rate constant of AZD9550 following repeat weekly SC doses
measured Day 1 to Day 65
Time to maximum observed concentration of AZD9550 following repeat weekly SC doses
measured Day 1 to Day 65
Apparent oral clearance of AZD9550 following repeat weekly SC doses
measured Day 1 to Day 65
Apparent volume of distribution of AZD9550 following repeat weekly SC doses
measured Day 1 to Day 65
Ratio for AUC of AZD9550 following repeat weekly SC doses
measured Day 1 to Day 65
Ratio for Cmax of AZD9550 following repeat weekly SC doses
measured Day 1 to Day 65
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed